대상포진 백신의 유효성에 대한 신속 체계적 문헌고찰
A Rapid Systematic Review of Effectiveness of Herpes Zoster Vaccine
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This study aims to investigate effectiveness of herpes zoster vaccines. Methods: Systematic searches on OVID-Medline and KoreaMed were performed on March 6th 2023. Randomized controlled trials (RCTs) and retrospective studies (RSs) were included, and a qualitative analysis was conducted. The outcomes of interest included protection against herpes zoster and related complications. Results: A total of six RCTs and twelve RSs were included in the analysis: one RCT and eight RSs of zoster vaccine live (ZVL), and five RCT and four RSs of recombinant zoster vaccine (RZV). Protection against herpes zoster by ZVL was approximately 50% in one year after vaccination, and the effectiveness decreased to 14%–39% after five years. Protection of herpes zoster by RZV was maximum 89% in two years, and the effectiveness decreased to 84% after 7–8 years and 73% after ten years. Conclusion: Compared to ZVL, RZV was judged to be more effective in protection against herpes zoster and showed a smaller decrease over time. We expect that this information can serve as a basis for policy making processes regarding the national immunization program in Korea.
Abstract
Objectives: This study aims to investigate effectiveness of herpes zoster vaccines. Methods: Systematic searches on OVID-Medline and KoreaMed were performed on March 6th 2023. Randomized controlled trials (RCTs) and retrospective studies (RSs) were included, and a qualitative analysis was conducted. The outcomes of interest included protection against herpes zoster and related complications. Results: A total of six RCTs and twelve RSs were included in the analysis: one RCT and eight RSs of zoster vaccine live (ZVL), and five RCT and four RSs of recombinant zoster vaccine (RZV). Protection against herpes zoster by ZVL was approximately 50% in one year after vaccination, and the effectiveness decreased to 14%–39% after five years. Protection of herpes zoster by RZV was maximum 89% in two years, and the effectiveness decreased to 84% after 7–8 years and 73% after ten years. Conclusion: Compared to ZVL, RZV was judged to be more effective in protection against herpes zoster and showed a smaller decrease over time. We expect that this information can serve as a basis for policy making processes regarding the national immunization program in Korea.
참고문헌 (31)
- Yun H, "Risk of herpes zoster in autoimmune and inflammatory diseases : implications for vaccination", Arthritis Rheumatol, 68, pp.2328~2337 (2016)
- Choi WS, "Disease burden of herpes zoster in Korea", J Clin Virol, 47, pp.325~329 (2010)
- Kawai K, "Systematic review of incidence and complications of herpes zoster : towards a global perspective", BMJ Open, 4, pp.e004833~ (2014)
- Choi JK, "Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015", Hum Vaccin Immunother, 15, pp.2554~2560 (2019)
- Kawai K, "Increasing incidence of herpes zoster over a 60-year period from a population-based study", Clin Infect Dis, 63, pp.221~226 (2016)
- Harpaz R, "Prevention of herpes zoster : recommendations of the Advisory Committee on Immunization Practices(ACIP)", MMWR Recomm Rep, 57, pp.1~30 (2008)
- Kwon SH, "Population-based epidemiologic study on herpes zoster in Korea : seven-year nationwide analysis from 2010 to 2016", Ann Dermatol, 31, pp.486~488 (2019)
- Dooling KL, "Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines", MMWR Morb Mortal Wkly Rep, 67, pp.103~108 (2018)
- Anderson TC, "Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years : recommendations of the Advisory Committee on Immunization Practices-United States, 2022", MMWR Morb Mortal Wkly Rep, 71, pp.80~84 (2022)
- Yu SY, "Prioritization of the introduction of new vaccines to the national immunization program" (2021), Korea Disease Control and Prevention Agency
- Korea University Research & Business Foundation, "Prioritization of the introduction of new vaccines to the national immunization program" (2023), Korea Disease Control and Prevention Agency
- Morrison VA, "Long-term persistence of zoster vaccine efficacy", Clin Infect Dis, 60, pp.900~909 (2015)
- Marin M, "Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status", Hum Vaccin Immunother, 11, pp.1157~1164 (2015)
- Blom K, "Effectiveness of the herpes zoster vaccine Zostavax® in Stockholm County, Sweden", Vaccine, 37, pp.4401~4406 (2019)
- Langan SM, "Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population : a cohort study", PLoS Med, 10, pp.e1001420~ (2013)
- Izurieta HS, "Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65years and older", Clin Infect Dis, 64, pp.785~793 (2017)
- McDonald BM, "The effectiveness of shingles vaccine among Albertans aged 50 years or older : a retrospective cohort study", Vaccine, 35, pp.6984~6989 (2017)
- Baxter R, "Long-term effectiveness of the live zoster vaccine in preventing shingles : a cohort study", Am J Epidemiol, 187, pp.161~169 (2018)
- Matthews I, "Assessing the effectiveness of zoster vaccine live : a retrospective cohort study using primary care data in the United Kingdom", Vaccine, 36, pp.7105~7111 (2018)
- Walker JL, "Effectiveness of herpes zoster vaccination in an older United Kingdom population", Vaccine, 36, pp.2371~2377 (2018)
- Lal H, "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults", N Engl J Med, 372, pp.2087~2096 (2015)
- Cunningham AL, "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older", N Engl J Med, 375, pp.1019~1032 (2016)
- Kovac M, "Complications of herpes zoster in immunocompetent older adults : incidence in vaccine and placebo groups in two large phase 3 trials", Vaccine, 36, pp.1537~1541 (2018)
- Boutry C, "The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster : interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70", Clin Infect Dis, 74, pp.1459~1467 (2022)
- Strezova A, "Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination", Open Forum Infect Dis, 9, pp.ofac485~ (2022)
- Izurieta HS, "Recombinant zoster vaccine(Shingrix) : real-world effectiveness in the first 2 years post-licensure", Clin Infect Dis, 73, pp.941~948 (2021)
- Lu A, "Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States", Ophthalmology, 128, pp.1699~1707 (2021)
- Sun Y, "Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older : a retrospective cohort study", Vaccine, 39, pp.3974~3982 (2021)
- Sun Y, "Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States : a claims-based cohort study", Clin Infect Dis, 73, pp.949~956 (2021)
- de Oliveira Gomes J, "Vaccines for preventing herpes zoster in older adults", Cochrane Database Syst Rev, 10, pp.CD008858~ (2023)
- Oxman MN, "Vaccination against herpes zoster and postherpetic neuralgia", J Infect Dis, 197(Suppl 2), pp.S228~S236 (2008)